Lääkkeiden vuorovaikutukset
What laboratory studies, small human studies and case reports actually show about kava interactions.
Sisältö
Premium Noble Kava
Tutustu sertifioituun laatuun ja puhtauteen viralliselta kumppaniltamme.
Käy Kava-mode.comLyhyesti & Ytimekkäästi
Kava can interact with medicines and other central nervous system depressants. Laboratory findings show several possible CYP inhibitions, but small human studies do not confirm one uniform pattern across all enzymes. Alcohol and sedatives in particular should not be self-combined; regular medication warrants individual review.
- ●Alkoholi – Additive drowsiness and impaired coordination are possible; concurrent use is not recommended
- ●Bentsodiatsepiinit – Possible additive CNS depression; combine only after professional review
- ●Antipsykootit – Sedation and pharmacokinetic interactions are possible; direct clinical data are limited
- ●Veritulpat – Controlled interaction data are lacking; the narrow therapeutic window requires medical review
Sytokromi-P450-järjestelmä
Sytokromi-P450-järjestelmä (CYP450) on entsyymiperhe maksassa, joka on vastuussa useimpien lääkkeiden metaboloitumisesta. Kun aine estää näitä entsyymejä, muiden aineiden hajoaminen hidastuu – niiden vaikutus ja sivuvaikutukset voivat näin ollen voimistua.
Miksi tämä on tärkeää?
Many medicines are metabolised by CYP enzymes. An in-vitro finding does not automatically mean clinically relevant inhibition in humans. Preparation, dose, duration and the medicine's therapeutic window determine practical relevance.
Mitä entsyymejä estetään?
Mathews et al. (2002) tested kava extract and individual kavalactones in human liver microsomes and found inhibition of several CYP enzymes. These are in-vitro findings, not clinical inhibition ratings in humans:
| Entsyymi | Estovoima | Tärkeät substraatit (esimerkit) |
|---|---|---|
| CYP1A2 | In-vitro finding | Kofeiini, teofylliini, klozapiini, olantsapiini |
| CYP2C9 | In-vitro finding | Varfariini, fenytoiini, tulehduskipulääkkeet (ibuprofeeni) |
| CYP2C19 | In-vitro finding | omepratsoli, diatsepaami, klopidogreeli |
| CYP2D6 | In-vitro finding | kodeiini, tramadoli, monet masennuslääkkeet |
| CYP3A4 | In-vitro finding | Bentsodiatsepiinit, statiinit, monet antibiootit |
Kliininen merkitys
Russmann et al. (2005) reported reduced CYP1A2 activity in chronic users of traditional aqueous kava. Gurley et al. (2005; 12 healthy volunteers, 28 days, 138 mg kavalactones/day), by contrast, found reduced CYP2E1 but no significant change in CYP1A2, CYP2D6 or CYP3A4/5. The human findings are small and preparation- and consumption-dependent, so they cannot predict every medicine interaction.
Korkean riskin yhdistelmät
The following combinations should be avoided or medically reviewed in advance. Reasons differ: some involve additive CNS effects or case reports, while others have only mechanistic signals and no controlled combination trials.
⚠ Alkoholi
Risiko: AVOID
Concurrent use of kava and alcohol is not recommended:
- 1.Additive CNS effects: Drowsiness, slower reactions and impaired coordination may increase.
- 2.Liver risk not quantified: A combined liver risk has not been quantified reliably; the combination is avoided because of this uncertainty.
- 3.Unpredictable intensity: Product, amount, drinking pattern and individual sensitivity make effects difficult to predict.
Do not use kava and alcohol together. The main practical reason is possible additive impairment of attention, reaction and coordination; the size of any additional liver risk is not reliably established.
⚠ Bentsodiatsepiinit & unilääkkeet
Risiko: PROFESSIONAL REVIEW
Do not combine benzodiazepines or Z-drugs with kava without medical review:
- •Additive sedation: Drowsiness and psychomotor impairment may increase.
- •CNS depression: Clinically relevant potentiation is possible; controlled combination trials are lacking.
- •Interpret CYP findings: CYP3A4 inhibition was observed in vitro but not consistently confirmed in small human studies.
Tapausraportti: Almeida & Grimsley (1996) described a semicomatose state in a 54-year-old man after reported kava and alprazolam use. A single case report is a warning signal but does not establish mechanism or frequency.
⚠ Antipsykootit
Risiko: PROFESSIONAL REVIEW
Individual medical review is appropriate before kava use with antipsychotics:
- •Sedation: Additive drowsiness or psychomotor impairment is possible.
- •Case reports: Individual reports describe movement disorders; frequency and causality are unclear.
- •CYP findings: Laboratory inhibition does not reliably predict the level of a specific medicine.
⚠ Veritulpat (verenvuotoa estävät lääkkeet)
Risiko: PROFESSIONAL REVIEW
Warfarin, phenprocoumon and other anticoagulants require professional review because of their narrow therapeutic window:
- •Mechanistic signal: CYP2C9 inhibition was observed in vitro; a clinical kava-warfarin interaction has not been established in controlled studies.
- •Monitor INR: Changes in co-used products should be coordinated with the treating clinician.
- •Bleeding risk: The baseline risk of anticoagulation makes self-testing inappropriate.
Use kava with anticoagulation only after individual medical review.
Kohtalaisen riskin yhdistelmät
Seuraavat yhdistelmät vaativat varovaisuutta ja niitä tulisi käyttää vain lääkärin kanssa keskustelun jälkeen. Annoksen säätö voi olla tarpeen.
Masennuslääkkeet
Risiko: PROFESSIONAL REVIEW
- • Pharmacokinetic interactions may occur depending on the product but are not clinically established as a class
- • Serotonin syndrome from kava is not established as a typical clinical effect
- • Additive drowsiness or dizziness are possible
- • Direct clinical combination data are limited
- • Review co-medication individually rather than inferring from in-vitro CYP data
- • MAO-B effects of individual kavalactones have been studied preclinically
- • Pawa et al. (2026) found MAO-A inhibition by flavokawain A in an in-vitro enzyme assay; humans and combination with MAO inhibitors were not studied
- • Do not self-combine with MAO inhibitors because medicine interactions can be serious
- • Obtain medical review before use
Antikonvulsantit (epilepsialääkkeet)
Risiko: PROFESSIONAL REVIEW
Fenytoiini, karbamatsepiini, valproaatti ja muut antikonvulsantit:
- •Pharmacokinetics: Altered levels are possible but cannot be predicted reliably for individual combinations.
- •CNS effects: Additive drowsiness or coordination problems are possible.
- •Seizure control: Changes in co-used products belong under professional supervision.
Epilepsian yhteydessä Kavaa tulisi käyttää vain lääkärin valvonnassa.
Parkinson-lääkkeet
Risiko: PROFESSIONAL REVIEW
Levodopa ja dopamiiniagonistit:
- •Mechanism unclear: Blanket clinical dopamine antagonism by kava has not been established.
- •Case reports: Individual reports describe worsening Parkinson symptoms; medical review is therefore needed.
With Parkinson's disease or related medication, use kava only after medical review.
Hepatotoksiset lääkkeet
Risiko: KOHTALAINEN
Lääkkeet, joilla on tunnettu hepatotoksinen potentiaali:
- •Parasetamoli/asetaminofeeni: Erityisesti suurilla annoksilla ongelmallinen
- •Statiinit: Atorvastatiini, simvastatiini jne. (CYP3A4-substraatit)
- •Metotreksaatti: Immunosuppressiivinen lääke, jolla on maksatoksisuus
- •Isoniatsidi: Tuberkuloosilääke
Additional liver risk is plausible but not quantified for every combination. Potentially hepatotoxic medication requires individual medical review.
Yhteenvetotaulukko vuorovaikutuksista
| Aineiden luokka | Esimerkit | Riski | Mechanismi |
|---|---|---|---|
| Alkoholi | Ethanoli | AVOID | Possible additive sedation and impaired coordination; liver risk not quantified |
| Bentsodiatsepiinit | Diazepami, loratsepaami, alpratsolaami | PROFESSIONAL REVIEW | Possible additive CNS depression; one case report, no controlled combination trials |
| Antipsykootit | Haloperidoli, olantsapiini, klozapiini | PROFESSIONAL REVIEW | Sedation or interactions possible; direct clinical data limited |
| Veritulpat | Varfariini, fenprokuomoni | PROFESSIONAL REVIEW | No controlled kava interaction established; narrow therapeutic window |
| SSRI:t | Fluoksetiini, sertraliini, paroksetiini | PROFESSIONAL REVIEW | Possible sedation or pharmacokinetics; no established kava serotonin syndrome |
| Antikonvulsantit | Fenytoiini, karbamatsepiini | PROFESSIONAL REVIEW | Possible additive CNS effects and unpredictable pharmacokinetics |
| Parkinson-lääkkeet | Levodopa, dopamiiniagonistit | PROFESSIONAL REVIEW | Case reports of symptom worsening; no blanket dopamine antagonism established |
| Statiinit | Atorvastatiini, simvastatiini | PROFESSIONAL REVIEW | Direct clinical interaction data are lacking; review liver and medication context |
| Opioidit | Kodeiini, tramadoli, morfiini | AVOID / REVIEW | Possible additive CNS depression |
| Kofeiini | Kahvi, energiajuomat | CAUTION | Human CYP1A2 findings are small and inconsistent |
Käytännön suositukset
Tarkistuslista ennen Kavan käyttöä
- 1.Tarkista lääkkeiden lista
Tarkista kaikki nykyiset lääkkeet vuorovaikutusten varalta
- 2.Konsultoi lääkäriä
Säännöllisesti lääkkeitä käyttävien tulisi kysyä lääkäriltä ennen Kavan käyttöä
- 3.Vältä alkoholia
Do not use kava and alcohol together. The main practical reason is possible additive impairment of attention, reaction and coordination; the size of any additional liver risk is not reliably established.
- 4.Aloita pienellä annoksella
Do not experiment with a self-selected lower kava dose while taking medicines; obtain professional review of the combination.
- 5.Seuraa oireita
Kiinnitä huomiota epätavalliseen väsymykseen, huimaukseen tai muihin oireisiin
Jatka turvallisuusluvussa
Tutkimuksiin perustuva
Panokset
Tämä wiki on kuratoitu resurssi, joka syntetisoi tutkimusta vertaisarvioituista tutkimuksista ja asiantuntijatutkiloista. Sitä ei ole kirjoittaneet yllä luetellut tutkijat, vaan se perustuu heidän julkaistuihin töihin.
Tieteelliset Lähteet
Tämän sivun tiedot perustuvat seuraaviin tieteellisiin tutkimuksiin ja julkaisuisiin:
Cytochrome P450 2E1 (CYP2E1) Is the Principal Enzyme Responsible for Urethane Metabolism
Hoffler U., El-Masri H.A., Ghanayem B.I. (2003) – Journal of Pharmacology and Experimental Therapeutics
Katso tutkimustaSisältö
Premium Noble Kava
Tutustu sertifioituun laatuun ja puhtauteen viralliselta kumppaniltamme.
Käy Kava-mode.com
Kava – Rauhan juurikasvi
Kattava opas vaikutuksesta, historiasta & kulttuurista.